請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40921完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林琬琬(Wan-Wan Lin) | |
| dc.contributor.author | Ming-Hui Tai | en |
| dc.contributor.author | 戴明慧 | zh_TW |
| dc.date.accessioned | 2021-06-14T17:06:52Z | - |
| dc.date.available | 2013-08-08 | |
| dc.date.copyright | 2008-08-08 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-28 | |
| dc.identifier.citation | References
Adams, J. M. and Cory, S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326. Agami, R., Blandino, G., Oren, M. and Shaul, Y. (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399, 809-813. Almasan, A. and Ashkenazi, A. (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14, 337-348. Apperley, J. F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8, 1018-1029. Ashkenazi, A. and Dixit, V. M. (1998) Death receptors: signaling and modulation. Science 281, 1305-1308. Ashkenazi, A. and Dixit, V. M. (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11, 255-260. Attoub, S., Rivat, C., Rodrigues, S., Van Bocxlaer, S., Bedin, M., Bruyneel, E., Louvet, C., Kornprobst, M., Andre, T., Mareel, M., Mester, J. and Gespach, C. (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62, 4879-4883. Barila, D. and Superti-Furga, G. (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18, 280-282. Barnhart, B. C., Alappat, E. C. and Peter, M. E. (2003) The CD95 type I/type II model. Semin Immunol 15, 185-193. Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J. and Jones, R. J. (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044. Belka, C. and Budach, W. (2002) Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol 78, 643-658. Belyanskaya, L. L., Marti, T. M., Hopkins-Donaldson, S., Kurtz, S., Felley-Bosco, E. and Stahel, R. A. (2007) Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 6, 66, 1-13. Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365. Chau, B. N., Chen, T. T., Wan, Y. Y., DeGregori, J. and Wang, J. Y. (2004) Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Mol Cell Biol 24, 4438-4447. Chawla-Sarkar, M., Leaman, D. W., Jacobs, B. S. and Borden, E. C. (2002) IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169, 847-855. Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D. and Rehemtulla, A. (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97, 1754-1759. Chung, K. C., Kim, S. M., Rhang, S., Lau, L. F., Gomes, I. and Ahn, Y. S. (2000) Expression of immediate early gene pip92 during anisomycin-induced cell death is mediated by the JNK- and p38-dependent activation of Elk1. Eur J Biochem 267, 4676-4684. Cross, T. G., Scheel-Toellner, D., Henriquez, N. V., Deacon, E., Salmon, M. and Lord, J. M. (2000) Serine/threonine protein kinases and apoptosis. Exp Cell Res 256, 34-41. Dan, S., Naito, M., Seimiya, H., Kizaki, A., Mashima, T. and Tsuruo, T. (1999) Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene 18, 1277-1283. Debatin, K. M., Poncet, D. and Kroemer, G. (2002) Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21, 8786-8803. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. and Joensuu, H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480. Denecker, G., Vercammen, D., Declercq, W. and Vandenabeele, P. (2001) Apoptotic and necrotic cell death induced by death domain receptors. Cell Mol Life Sci 58, 356-370. Di Lorenzo, G., Tortora, G., D'Armiento, F. P., De Rosa, G., Staibano, S., Autorino, R., D'Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A. R. and Ciardiello, F. (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8, 3438-3444. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2, 561-566. El-Deiry, W. S. (2001) Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 8, 1066-1075. Elmore, S. (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35, 495-516. Falschlehner, C., Emmerich, C. H., Gerlach, B. and Walczak, H. (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39, 1462-1475. Frame, D. (2007) New strategies in controlling drug resistance. J Manag Care Pharm 13, 13-17. Gajewski, T. F. (2007) On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 25, 1305-1307. George, D. (2003) Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. Adv Exp Med Biol 532, 141-151. Goldman, J. M. and Melo, J. V. (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1084-1086. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M. and Wang, J. Y. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809. Gordon, M. Y., Dowding, C. R., Riley, G. P., Goldman, J. M. and Greaves, M. F. (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328, 342-344. Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G. and Klein, J. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61, 82-90 Green, D. R. (1998) Apoptotic pathways: the roads to ruin. Cell 94, 695-698. Hamai, A., Richon, C., Meslin, F., Faure, F., Kauffmann, A., Lecluse, Y., Jalil, A., Larue, L., Avril, M. F., Chouaib, S. and Mehrpour, M. (2006) Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Oncogene 25, 7618-7634. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A. and Zigler, A. J. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932. Henriksen, R., Funa, K., Wilander, E., Backstrom, T., Ridderheim, M. and Oberg, K. (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53, 4550-4554. Herr, I., Wilhelm, D., Meyer, E., Jeremias, I., Angel, P. and Debatin, K. M. (1999) JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ 6, 130-135. Hofer, M. D., Fecko, A., Shen, R., Setlur, S. R., Pienta, K. G., Tomlins, S. A., Chinnaiyan, A. M. and Rubin, M. A. (2004) Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6, 503-512. Holdhoff, M., Kreuzer, K. A., Appelt, C., Scholz, R., Na, I. K., Hildebrandt, B., Riess, H., Jordan, A., Schmidt, C. A., Van Etten, R. A., Dorken, B. and le Coutre, P. (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34, 181-185. Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., Maclean, M., Lo, L., Fox, N. L. and Oza, A. M. (2008) A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clin Cancer Res 14, 3450-3455. Hu, W. H., Johnson, H. and Shu, H. B. (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274, 30603-30610. Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M. and Kelley, R. F. (2000) A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39, 633-640. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P. and Zhou, T. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7, 954-960. Inoue, S., MacFarlane, M., Harper, N., Wheat, L. M., Dyer, M. J. and Cohen, G. M. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11 Suppl 2, S193-206. Jiang, X., Lopez, A., Holyoake, T., Eaves, A. and Eaves, C. (1999) Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 96, 12804-12809. Jin, Z., McDonald, E. R., 3rd, Dicker, D. T. and El-Deiry, W. S. (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279, 35829-35839. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B. and Demetri, G. D. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344, 1052-1056. Jones, E. V., Dickman, M. J. and Whitmarsh, A. J. (2007) Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J 405, 617-623. Jost, C. A., Marin, M. C. and Kaelin, W. G., Jr. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191-194. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F. and Caput, D. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819. Kelley, S. K., Harris, L. A., Xie, D., Deforge, L., Totpal, K., Bussiere, J. and Fox, J. A. (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299, 31-38. Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., Deforge, L., Pai, R., Hymowitz, S. G. and Ashkenazi, A. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280, 2205-2212. Kikuchi, S., Nagai, T., Kunitama, M., Kirito, K., Ozawa, K. and Komatsu, N. (2007) Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 98, 1949-1958. Kim, K., Fisher, M. J., Xu, S. Q. and el-Deiry, W. S. (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6, 335-346. Kim, K., Takimoto, R., Dicker, D. T., Chen, Y., Gazitt, Y. and El-Deiry, W. S. (2001) Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 18, 241-247. Kimberley, F. C. and Screaton, G. R. (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14, 359-372. Kondo, K., Yamasaki, S., Sugie, T., Teratani, N., Kan, T., Imamura, M. and Shimada, Y. (2006) Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer 118, 230-242. Krammer, P. H. (2000) CD95's deadly mission in the immune system. Nature 407, 789-795. Kroemer, G., Dallaporta, B. and Resche-Rigon, M. (1998) The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60, 619-642. Kyriakis, J. M. and Avruch, J. (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81, 807-869. Lacour, S., Micheau, O., Hammann, A., Drouineaud, V., Tschopp, J., Solary, E. and Dimanche-Boitrel, M. T. (2003) Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22, 1807-1816. LeBlanc, H. N. and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10, 66-75. Lee, M. W., Park, S. C., Yang, Y. G., Yim, S. O., Chae, H. S., Bach, J. H., Lee, H. J., Kim, K. Y., Lee, W. B. and Kim, S. S. (2002) The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett 512, 313-318. Li-Weber, M. and Krammer, P. H. (2003) Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15, 145-157. Machuy, N., Rajalingam, K. and Rudel, T. (2004) Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ 11, 290-300. McCarthy, J. V. and Cotter, T. G. (1997) Cell shrinkage and apoptosis: a role for potassium and sodium ion efflux. Cell Death Differ 4, 756-770. Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., Knight, R. A., Green, D. R., Thompson, C. and Vousden, K. H. (2004) p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279, 8076-8083. Melino, G., Lu, X., Gasco, M., Crook, T. and Knight, R. A. (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28, 663-670. Nagar, B. (2007) c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). J Nutr 137, S1518S-1523. Nimmanapalli, R., Porosnicu, M., Nguyen, D., Worthington, E., O'Bryan, E., Perkins, C. and Bhalla, K. (2001) Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7, 350-357. Norbury, C. J. and Hickson, I. D. (2001) Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol 41, 367-401. Ono, K. and Han, J. (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12, 1-13. Ozoren, N. and El-Deiry, W. S. (2002) Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4, 551-557. Peus, D., Vasa, R. A., Beyerle, A., Meves, A., Krautmacher, C. and Pittelkow, M. R. (1999) UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol 112, 751-756. Poh, T. W., Huang, S., Hirpara, J. L. and Pervaiz, S. (2007) LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 14, 1813-1825. Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R. and Pawson, T. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13, 764-773. Ramadan, S., Terrinoni, A., Catani, M. V., Sayan, A. E., Knight, R. A., Mueller, M., Krammer, P. H., Melino, G. and Candi, E. (2005) p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 331, 713-717. Roulston, A., Reinhard, C., Amiri, P. and Williams, L. T. (1998) Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273, 10232-10239. Sanchez-Prieto, R., Sanchez-Arevalo, V. J., Servitja, J. M. and Gutkind, J. S. (2002) Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21, 974-979. Sayan, A. E., Sayan, B. S., Gogvadze, V., Dinsdale, D., Nyman, U., Hansen, T. M., Zhivotovsky, B., Cohen, G. M., Knight, R. A. and Melino, G. (2008) p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 27, 4363-4372 Shaul, Y. (2000) c-Abl: activation and nuclear targets. Cell Death Differ 7, 10-16. Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G., Paul, J. T. and Gibson, S. B. (2005) Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 25, 5404-5416. Singer, C. F., Hudelist, G., Lamm, W., Mueller, R., Czerwenka, K. and Kubista, E. (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11, 861-869. Stadheim, T. A. and Kucera, G. L. (2002) c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res 26, 55-65. Su, R. Y., Chao, Y., Chen, T. Y., Huang, D. Y. and Lin, W. W. (2007) 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther 6, 1562-1571. Sun, H. Y., Wang, N. P., Halkos, M., Kerendi, F., Kin, H., Guyton, R. A., Vinten-Johansen, J. and Zhao, Z. Q. (2006) Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 11, 1583-1593. Tillman, D. M., Izeradjene, K., Szucs, K. S., Douglas, L. and Houghton, J. A. (2003) Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63, 5118-5125. Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., Jonak, Z. L., Johnson, R., DeWitte, M., Martino, H., Audette, C., Maes, K., Chari, R. V., Lambert, J. M. and Rowinsky, E. K. (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21, 211-222. Uno, K., Inukai, T., Kayagaki, N., Goi, K., Sato, H., Nemoto, A., Takahashi, K., Kagami, K., Yamaguchi, N., Yagita, H., Okumura, K., Koyama-Okazaki, T., Suzuki, T., Sugita, K. and Nakazawa, S. (2003) TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101, 3658-3667. Van Etten, R. A. (1999) Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 9, 179-186. Van Etten, R. A. (2004) Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28 Suppl 1, S21-28. Vanoosten, R. L., Moore, J. M., Ludwig, A. T. and Griffith, T. S. (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11, 542-552. Wajant, H., Gerspach, J. and Pfizenmaier, K. (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16, 55-76. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V. and Boldin, M. P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17, 331-367. Wang, J. Y. (1993) Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev 3, 35-43. Wang, J. Y. (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 19, 5643-5650. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J. and Greenberg, M. E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331. Yamaguchi, K., Uzzo, R. G., Pimkina, J., Makhov, P., Golovine, K., Crispen, P. and Kolenko, V. M. (2005) Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 24, 5868-5877. Yuan, Z. M., Huang, Y., Ishiko, T., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1997) Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94, 1437-1440. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399, 814-817. Zhang, L. and Fang, B. (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12, 228-237. Zou, W., Liu, X., Yue, P., Zhou, Z., Sporn, M. B., Lotan, R., Khuri, F. R. and Sun, S. Y. (2004) c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 64, 7570-7578. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40921 | - |
| dc.description.abstract | 癌症的治療在研發出多種細胞毒殺的化學治療藥物之後雖然大有進展，但腫瘤細胞對這些藥物所衍生出來的抗藥性仍舊是治療上的主要障礙。過去研究發現，TRAIL會選擇性的引起腫瘤細胞的死亡，而同時對於正常組織細胞幾乎沒有毒性；在本論文中，為了研究TRAIL合併其他臨床使用藥物的潛力，我們將探討Gleevec與TRAIL合併使用之下，對癌症細胞所引起的效果以及分子機制。Gleevec是臨床上用來治療慢性骨髓性白血病的首選抗癌藥物，其作用是可以有效抑制蛋白酪氨酸激酶c-Abl 及Bcr-Abl的作用。本篇研究中，我們比較了不同之人類癌症細胞株的毒性測試後，發現K562 (人類白血病細胞株)合併使用Gleevec 和TRAIL可以增加對細胞的毒性，然而，在人類大腸癌細胞 HCT116和SW480卻出現相反的結果。在上述兩株細胞中，0.1-1 μM 濃度下的Gleevec可以保護TRAIL所引發的細胞凋亡；但是在其他的細胞株中 (HT29, PC3, LNCaP, HaCaT 以及p53-null HCT116 細胞) 就沒有此現象存在。此外我們發現Gleevec可以減輕TRAIL所引起JNK和p38的活化，進而減緩對細胞的毒性。在HCT116細胞中，我們發現利用c-Abl 和 p73的小型干擾RNA可同時減弱TRAIL所誘發的細胞毒性和其所誘發激酶的活性，而此時Gleevec的保護效果就無法顯現。但是Gleevec的作用並不存在於對壓力誘導劑anisomycin所引發的激酶活化及細胞毒性。總結來說，我們認為在人類大腸癌細胞中TRAIL所產生的毒性是需經由p38 及 JNK的調控來增加蛋白凋亡酶的活化。經由實驗結果我們認為TRAIL的細胞毒性亦同時需要c-Abl及p73的參與，且對下游p38 及 JNK的調控是必要的步驟。這些結果提供了一個新的經由c-Abl/p73路徑來調控TRAIL引起酵素激酶JNK及p38活性及細胞凋亡的機制，以及未來在臨床上合併使用TRAIL和Gleevec發展治療人類大腸癌時應多加考慮的因素。 | zh_TW |
| dc.description.abstract | Even though there are many advances in the cancer therapy following the introduction of cytotoxic chemotherapeutic drugs, the development of drug combination to decrease cancer resistance and side effect still needs more efforts. TRAIL has been shown to selectively induce tumor cell death, and has minimal toxicity against normal tissues. In seeking to develop combination validity of TRAIL, we elucidate the effects of Gleevec in TRAIL-induced cancer cell death. Gleevec, a clinical drug effectively used for chronic myelogenous leukemia, is a tyrosine kinase inhibitor against c-Abl and Bcr-Abl. Studying cell viability changes in various human cancer cells, we found Gleevec can induce the increased cytotoxicity in TRAIL-treated K562 leukemia cells, but achieve an opposite effect in HCT116 and SW480 colon cancer cells. In both cancer cells, TRAIL-induced cell apoptosis is reduced by Gleevec in a concentration range of 0.1-1μM. No alteration of cell toxicity following TRAIL and Gleevec co-treatment is observed in HT29, PC3, LNCaP, HaCaT and p53-null HCT116 cells. JNK and p38 MAPK inhibitors effectively block TRAIL-induced toxicity. Accordingly Gleevec can attenuate TRAIL-induced JNK and p38 activation and cell apoptosis. In addition, siRNA targeting knockdown of c-Abl and p73 reduce TRAIL-induced cytotoxicity and render HCT116 cells less responsive to stress kinase activation. Moreover, in the downregulation condition of p73, Gleevec no longer induces cytoprotective effect. However, Gleevec does not affect cell death and stress kinase activation caused by anisomycin. All together it is suggested that in addition to activation of classical caspase cascade, TRAIL-induced apoptosis in human HCT116 colon cancer cells requires p38 and JNK activation. We propose both kinase activations induced by TRAIL depend on c-Abl activity and its downstream targeting effector p73. Our results provide a novel mechanism for stress kinase activation by death receptors, and additional concern in developing combination cancer therapy with TRAIL and Gleevec in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-14T17:06:52Z (GMT). No. of bitstreams: 1 ntu-97-R95443003-1.pdf: 1547167 bytes, checksum: a6842ffbbeedc634219f4a2f21df8470 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | Abbreviations ………………………………………….……I
Abstract ………………………………………………… …II 中文摘要 ……………………………………………… …IV Introduction …………………………………………………1 Materials and Methods ……………………………………16 Results …………………………………… ……………… 22 Discussion …………………………………………… ……31 Figure …………………………………………………… …40 Table …………………………………………………………56 Appendix …………………………………………… ………57 References …………………………………………… ……59 | |
| dc.language.iso | en | |
| dc.title | 探討Gleevec在人類大腸癌細胞中TRAIL所誘發細胞凋亡之訊息傳遞路徑 | zh_TW |
| dc.title | Molecular mechanisms for Gleevec reduction of TRAIL-induced apoptosis in HCT116 colon cancer cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊春茂,顏茂雄,蘇銘嘉 | |
| dc.subject.keyword | c-Abl抑制劑l,人類大腸癌細胞, | zh_TW |
| dc.subject.keyword | TRAIL,Gleevec,MAPK,Colon cancer cells, | en |
| dc.relation.page | 67 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-07-29 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 目前未授權公開取用 | 1.51 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。